Journal
JOURNAL OF PATHOLOGY
Volume 238, Issue 2, Pages 311-320Publisher
WILEY-BLACKWELL
DOI: 10.1002/path.4634
Keywords
cystic fibrosis; pancreas; diabetes; cystic fibrosis transmembrane conductance regulator; pathology; pancreatic insufficiency
Funding
- National Heart, Lung and Blood Institute [HL51670, HL091842, HL123482]
- National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK054759, R24 DK096518]
- Cystic Fibrosis Foundation
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL091842, R24HL123482, P01HL051670] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK096518, P30DK054759] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The pancreas is one of the earliest, and most commonly affected, organs in patients with cystic fibrosis (CF). Studying the pathogenesis of pancreatic disease is limited in CF patients, due to its early clinical onset, co-morbidities and lack of tissue samples from the early phases of disease. In recent years, several new CF animal models have been developed that have advanced our understanding of both CF exocrine and endocrine pancreatic disease. Additionally, these models have helped us to better define the influence of pancreatic lesions on CF disease progression in other organs, such as the gastrointestinal tract and lung. Copyright Copyright (c) 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available